Troubled Dendreon gets EC OK for Provenge; Acacia launches pivotal studies;

@FierceBiotech: ICYMI yesterday: CDC director warns antibiotics pipeline 'nearly empty.' Story | Follow @FierceBiotech

@JohnCFierce: Regado CEO moves the goal line after a rare biotech IPO misfire. More | Follow @JohnCFierce

> Dendreon shares ($DNDN) jumped about 10% this morning after the biotech reported that the European Commission had approved Provenge, its struggling prostate cancer therapy, which has experienced profound trouble in developing a market in the U.S. Story

> The U.K.'s Acacia Pharma launched two pivotal Phase III studies of APD421 in the prevention of post-operative nausea and vomiting. Release

> The European Commission has also approved Sanofi's ($SNY) MS drug Lemtrada, which was developed by Genzyme. Story

Medical Device News

@FierceMedDev: Special Report: 'Big' med tech M&A deals getting smaller. Feature | Follow @FierceMedDev

@DamianFierce: VisionCare landed up to $15M to market its AMD-treating eye implant. News | Follow @DamianFierce

@MarkHFierce: The U.S. will now have the first permanent implant designed to treat enlarged prostates. Expect a gradual launch. ICYMI yesterday | Follow @MarkHFierce

@MichaelGFierce: Abbott snags CE mark for diabetes monitor. Item | Follow @MichaelGFierce

> Europe risks more delays on device reg reform. More

> Medtronic cuts ribbon on $10M Irish R&D shop. Story

> Boston Scientific debuts teaching, R&D centers in China. Article

Pharma News

@FiercePharma: Now armed with EU nod for Lemtrada, Sanofi preps to launch its multiple sclerosis duo (with Aubagio). Release (PDF) | Follow @FiercePharma

@CarlyHFierce: Whistleblower codenamed Zorro implicates Novartis' Alcon division in Chinese bribery scandal. More from The Financial Times Follow @CarlyHFierce

> Novartis faces second set of bribery claims in China. More

> FDA approves Teva's generic of Roche blockbuster Xeloda. Article

Pharma Manufacturing News

@EricPFierce: Now that Ranbaxy's Mohali plant falls under FDA consent decree, oversight ramps up significantly. Article | Follow @EricPFierce

> Cargill invests $15M in French alginate plant. Item

> Hospira recalls bupivacaine because of steel particles in vials. Story

> Strides gets FDA warning for plant Mylan is buying. More

> J&J sues Ben Venue over Doxil shortage. Report

Biotech Research News

@EmilyMFierce: Initial focus of BRAIN Initiative laid out, but are the goals any clearer than they were in April? Check out the story and weigh in | Follow @EmilyMFierce

> Visterra antibody shows promise in preclinical study as universal flu vaccine. Item

> NIH partners with Eli Lilly, others on rare diseases. Article

> Experimental vaccine clears monkeys of HIV-like virus. More

> Genia Technologies, Columbia, Harvard nab $5.3M NIH grant for genome sequencing. Story

And Finally... No, this isn't an image of a far-away galaxy. It's a map of 873,344 scientific papers across various disciplines. 

Suggested Articles

The ambitious target is enabled by an AI discovery platform that Healx thinks gives it a scalability that has more in common with tech than biotech.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.